We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI (SCI)

This study is currently recruiting participants.
Verified September 2017 by Neuralstem Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01772810
First Posted: January 21, 2013
Last Update Posted: September 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Neuralstem Inc.
  Purpose
This is a safety study of human spinal cord-derived neural stem cell (HSSC) transplantation for the treatment of chronic spinal cord injury.

Condition Intervention Phase
Spinal Cord Injury (SCI) Drug: Human spinal cord stem cells. Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Single-site, Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI

Resource links provided by NLM:


Further study details as provided by Neuralstem Inc.:

Primary Outcome Measures:
  • Adverse events and clinically significant laboratory abnormalities [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Graft survival in the transplant site as determined by MRI (for Group A) and via autopsy, if one is completed. [ Time Frame: Month 60 ]
    Effectiveness of immunosuppression as determined by absence of donor-specific HLA antibodies.


Other Outcome Measures:
  • EMG, SCIM, ISNC SCI, and Bowel and bladder follow-up [ Time Frame: 60 months ]

Estimated Enrollment: 8
Actual Study Start Date: August 2014
Estimated Study Completion Date: December 2022
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Surgical implantation of human spinal cord stem cells
Surgical implantation of human spinal cord derived neural stem cells.
Drug: Human spinal cord stem cells.
Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
Other Name: spinal cord injury (SCI)

Detailed Description:
Phase I, open-label, single-site, safety study of HSSC transplantation for the treatment of chronic spinal cord injury (SCI). Group A enrolled 4 subjects with a cord injury at T2-T12; Group B will enroll 4 subjects with a C5-C7 cord injury. Study period will be 6 months post-operative. Post-study, subjects will be followed for an additional 54 months.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Lives within 500 miles of study center (For Group B)

    1. Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) [per Health Insurance Portability and Accountability Act (HIPAA) Privacy Ruling] and comply with the study procedures
    2. Men and women 18-65 years old
    3. Women must have a negative serum pregnancy test and practice an acceptable method of contraception or be of non-childbearing potential (post-menopausal for at least 2 years or who have undergone hysterectomy or oophorectomy or surgical sterilization)
    4. At least 1 year but no more than 2 years from time of injury at the time of surgery
    5. SCI injury classified as AIS-A complete as confirmed by the PI and a Physical Medicine and Rehabilitation doctor or other SCI Medicine board certified physician based on a complete ISNC SCI examination
    6. Neurologic level of injury:

      1. Group A: injury within cord segments T2-T12;
      2. Group B: injury within cord segments C5-C7
    7. Confirmation of bone fusion by CT scan
    8. Agrees to the visit schedule as outlined in the informed consent
    9. All required vaccinations current at the time of enrollment: tetanus/diptheria (TDAP), herpes zoster/shingles (Zostavax®: within last 10 years and must be prior to surgery), pneumonia (Pneumovax®), seasonal/H1N1 flu vaccines (as appropriate for season). Any missing vaccination will be provided at the screening if consented by the otherwise eligible patient who will then be scheduled for surgery no less than 30 days post vaccination.

Exclusion Criteria:

  1. SCI due to penetrating trauma such as gun shot or stabbing wound
  2. SCI injuries involving complete spinal cord transection
  3. Etiology of paraplegia or weakness related to other or additional neurologic process
  4. MRI evidence of syrinx, multiple cysts, or a cyst with greater than 2cm in length or injury site involving greater than 2cm of the cord
  5. Current or peak Panel Reactive Antibody (PRA) due to alloantibodies > 20% receiving their first allograft or presence of antibodies against HLA of the donor cells
  6. Receipt of any investigational drug or device within 30 days prior to surgery
  7. Receipt of any cell infusion other than blood transfusion
  8. Any concomitant medical disease or condition noted below:

    1. Coagulopathy with INR > 1.4 at the time of screening
    2. Active infection
    3. Active hypotension requiring vasopressor therapy
    4. Skin breakdown over the site of surgery
    5. History of Malignancy (except for non-melanoma skin cancer)
    6. Primary or secondary immune deficiency
    7. Persistent MRI artifact that would prevent imaging post-op h. Creatinine >1.5, liver function tests (SGOT/SGPT, Bilirubin, Alk Phos) > 2x upper limit of normal, hematocrit/hemoglobin < 30/10, total WBC < 3000, uncontrolled hypertension (systolic > 180 or diastolic > 100) or uncontrolled diabetes (defined as hemoglobin A1C >8), evidence of GI bleeding by hemoccult test, positive tuberculosis, hepatitis B or C, or human immunodeficiency virus (HIV)
  9. Presence of any of the following conditions:

    1. Current drug abuse or alcoholism
    2. Unstable medical conditions
    3. Unstable psychiatric illness including psychosis and untreated major depression
  10. Any condition that the Investigator or primary physician feels may interfere with participation in the study
  11. Any condition that the surgeon feels may pose complications for the surgery
  12. Known hypersensitivity to basiliximab, tacrolimus or mycophenolate mofetil
  13. Inability to provide informed consent as determined by screening protocol.
  14. Stage III or above decubitus wound, other open wound, or active colostomy;
  15. Autoimmune diseases, for which chronic corticosteroids or immunosuppression therapy may be needed;
  16. Implanted spine stimulator;
  17. Uncontrolled spasticity;
  18. Uncontrolled neuropathic pain
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01772810


Contacts
Contact: Dr. Ciacci's Research Group 844-317-7836 (STEM) alphastemcellclinic@ucsd.edu

Locations
United States, California
UCSD Medical Center, Division of Neurosurgery Recruiting
San Diego, California, United States, 92103-8893
Contact: Dr. Ciacci's Research Group    844-317-7836    alphastemcellclinic@ucsd.edu   
Principal Investigator: Joseph Ciacci, MD         
Sub-Investigator: Martin Marsala, MD         
Sponsors and Collaborators
Neuralstem Inc.
Investigators
Principal Investigator: Joseph Ciacci, MD UCSD Medical Center, Division of Neurosurgery
  More Information

Additional Information:
Responsible Party: Neuralstem Inc.
ClinicalTrials.gov Identifier: NCT01772810     History of Changes
Other Study ID Numbers: NS2010-1
First Submitted: January 14, 2013
First Posted: January 21, 2013
Last Update Posted: September 11, 2017
Last Verified: September 2017

Keywords provided by Neuralstem Inc.:
Paralysis, spinal cord injury, chronic spinal cord injury, cspine injury, neck injury

Additional relevant MeSH terms:
Spinal Cord Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries